Clinical Trial

Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial

Study acronym: PICASSO
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated June 9, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, open-label, effectiveness study designed to evaluate the use of Tenofovir, Lamivudine, and Dolutegravir in people with newly diagnosed HIV-1 infection initiating first-line Antiretroviral Therapy with Cabotegravir-Long-acting Pre-Exposure Prophylaxis exposure in the preceding 12 months. Participants will be followed up for a period of 12 months from enrolment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-26.
Status change: Active, Not Recruiting → Recruiting 2026-06-04
Trial Details
NCT Number NCT06485154
Lead Sponsor University of Witwatersrand, South Africa
Collaborators: Bill and Melinda Gates Foundation
Conditions HIV Prevention
Enrollment 100 participants
Start Date 2024-06-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-09